EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The many pathways driving liver inflammation in MASH

Herbert Tilg, Timon E Adolph, Stefano Romeo, Rohit Loomba

Cell Metabolism · 2026-06 · 38 (6) · 1054-1074

DOI: 10.1016/j.cmet.2026.02.018 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cell Metabolism, 2026-06. Verfasst von Herbert Tilg und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Innsbruck, Austria. Ele…. Hauptthemen laut MEDLINE: Inflammation, Fatty Liver. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 275 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, affecting one-third of the global population. Most patients exhibit simple steatosis, whereas up to 20% develop metabolic dysfunction-associated steatohepatitis (MASH), potentially culminating in liver cirrhosis and hepatocellular carcinoma. Diverse parallel mechanisms contribute to the development of MASH, which are fueled by hepatic lipotoxicity, intestinal dysbiosis, and pro-inflammatory diets shaping innate and adaptive immune responses. Moreover, adipose tissue is driving systemic inflammation in obesity, contributing to the inflammatory burden in obesity-related MASH. Polygenetic and multiomic risk scores identify distinct types of MASLD with dominant aggressive liver disease or extrahepatic cardiometabolic disease. Here, we review the complexity of multiple parallel inflammatory hits in MASH and delineate that most current MASH drugs exert pleiotropic metabolic and anti-inflammatory properties. These new therapies will change the clinical management of this disease in the near future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InflammationFatty LiverHumansAnimalsLiver

Stichwörter der Autor:innen

cytokinesfibrosisinflammationmetabolism dysfunction-associated steatotic liver disease

Autor:innen und Institutionen

  • Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: herbert.tilg@i-med.ac.at.
  • Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Innsbruck, Austria.
  • Department of Medicine (H7), CeRM, Karolinska Institute, Huddinge, Sweden; Medical Unit Endocrinology, Theme Inflammation and ageing, Karolinska University Hospital, Huddinge, Sweden; Department of Molecular and Clinica…
  • MASLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.

Förderung

  • European Research Council

Zitieren

APA

Tilg, H., Adolph, T. E., Romeo, S., & Loomba, R. (2026). The many pathways driving liver inflammation in MASH. Cell Metabolism, 38(6), 1054-1074. https://doi.org/10.1016/j.cmet.2026.02.018

Vancouver

Tilg H, Adolph TE, Romeo S, Loomba R. The many pathways driving liver inflammation in MASH. Cell Metabolism. 2026;38(6):1054-1074. doi:10.1016/j.cmet.2026.02.018

BibTeX
@article{Tilg2026,
  author = {Tilg, Herbert and Adolph, Timon E and Romeo, Stefano and Loomba, Rohit},
  title = {The many pathways driving liver inflammation in MASH},
  journal = {Cell Metabolism},
  year = {2026},
  volume = {38},
  number = {6},
  pages = {1054--1074},
  doi = {10.1016/j.cmet.2026.02.018}
}
Kostenlos starten →